Each 1-hour session will include 3 topic modules focused on current management, emerging research and novel agents and strategies under active investigation for MM. Each event will employ an identical format that will include the following elements:

• • Discussion of Steering Committee Members’ Treatment Recommendations
• • Review of Available Clinical Research Findings
• • Integration of Interactive Audience Polling Results

MODULE 1 Clinical Decision-Making for Patients with Newly Diagnosed MM MODULE 2 Contemporary Management of Relapsed/Refractory MM MODULE 3 Novel Agents and Strategies in Late-Stage Development

Target Audience
This activity is intended for medical oncologists, hematologists and other healthcare providers involved in the treatment of MM.

Learning Objectives

• Discuss available research data informing the use of monoclonal antibody therapy directed at CD38 as a component of induction therapy for patients with MM eligible or ineligible for stem cell transplant, and effectively identify when and how this strategy should be integrated into the clinical management of this disease.
• Customize induction, consolidation and maintenance therapeutic approaches for active MM in the post-transplant and nontransplant settings, considering patient- and disease-related factors, including cytogenetic profile.
• Evaluate research data supporting a role for minimal residual disease (MRD) status in predicting long-term outcomes with therapy, and use this information to determine the potential role of MRD assays in protocol and nonresearch management of MM.
• Apply published research data and other clinical factors in the best-practice selection, sequencing or combining of available therapies in the nonresearch care of patients with relapsed/refractory MM.
• Discuss available data documenting the activity of chimeric antigen receptor T-cell therapy and antibody-drug conjugates designed to target BCMA (B-cell maturation antigen), and use this knowledge to identify patients with MM who may be appropriate for these therapeutic approaches on clinical trials.
• Assess the mechanisms of action of, available data with and ongoing clinical trials evaluating other novel, investigational approaches for MM, and consider the potential role of these therapies in clinical practice.

Physician Competencies To Be Addressed
Patient Care and Procedural Skills, Medical Knowledge.

CME Credit Form
CME and ABIM MOC credit form links will be emailed to each participant within 5 business days of the conclusion of the activity.

Contact Information
For questions regarding credit, please contact USF Health at cpdsupport@usf.edu.

Accreditation Statement
USF Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

USF Health designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM) — Maintenance of Certification (MOC)
Successful completion of this CME activity, which includes participation in the evaluation component and a short post-test, enables the participant to earn up to 1 Medical Knowledge MOC point in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information. For those clinicians wishing to receive ABIM MOC credit for attending, you will receive an email after the event with instructions.

Privacy Disclosure
Learners provide permission for USF Health to share their completion data with ACCME, who will transmit same on their behalf to ABIM. Within 60 days of the end of the activity, USF Health will upload to ACCME the participant data of physicians who have met the ABIM MOC Points requirements; ACCME will transmit the same to ABIM.

Completion Requirements
Physicians seeking ABIM Points will be required to take an evaluation/post-test passing with a score of 80% or higher.

Disclaimer
The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical/clinical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient’s medical condition.

Equal Opportunity Statement
USF Health is an Equal Opportunity/Affirmative Action/Equal Access Institution.

Potential Conflicts of Interest
USF Health adheres to The Standards for Integrity and Independence in Accredited Continuing Education in all of its continuing professional development activities. It is USF Health’s policy that all persons in a position to influence content in this activity disclose any financial relationship with an ineligible organization. USF Health has mitigated all conflicts of interest.

STEERING COMMITTEE — The following faculty reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Kenneth C Anderson, MD
Kraft Family Professor of Medicine
Harvard Medical School
Director, Jerome Lipper Multiple Myeloma Center
and LeBow Institute for Myeloma Therapeutics
Dana-Farber Cancer Institute
Boston, Massachusetts

Advisory Committee: Bristol-Myers Squibb Company, Gilead Sciences Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Oncology; Consulting Agreements: Amgen Inc, Pfizer Inc, Precision BioSciences, Sumitomo Dainippon Pharma Oncology Inc; Ownership Interest: Scientific founder of C4 Therapeutics and OncoPep.

Rafael Fonseca, MD
Getz Family Professor of Cancer
Director for Innovation and Transformational Relationships
Interim Executive Director of the Mayo Clinic Comprehensive Cancer Center
Chair, Department of Internal Medicine
Distinguished Mayo Investigator
Mayo Clinic in Arizona
Phoenix, Arizona

Advisory Committee: Adaptive Biotechnologies Corporation, ONCOtracker Inc; Consulting Agreements: AbbVie Inc, Aduro Biotech, Amgen Inc, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Merck, Novartis, ONCOtracker Inc, Pharmacyclics LLC, an AbbVie Company, Sanofi Genzyme, Takeda Oncology.

Morie A Gertz, MD, MACP
Consultant, Hematology
Mayo Clinic
Rochester, Minnesota

Advisory Board: Ionis Pharmaceuticals; Consulting Agreements: Akcea Therapeutics, Alnylam Pharmaceuticals Inc, Prothena; Data and Safety Monitoring Board/Committee: AbbVie Inc, Celgene Corporation; Honoraria: Akcea Therapeutics, Ambry Genetics, Amgen Inc, Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Pfizer Inc (to Institution), Sanofi Genzyme; Stock Options: Aurora Biopharma.

Irene M Ghobrial, MD
Professor of Medicine

Director, Clinical Investigator Research Program

Director, Michele and Stephen Kirsch Laboratory
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Accommodations: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Novartis, Takeda Oncology; Advisory Committee and Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cellectar Biosciences Inc, GlaxoSmithKline, Novartis, Sanofi Genzyme, Takeda Oncology; Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Takeda Oncology.

Sergio A Giralt, MD
Deputy Division Head of Hematologic Malignancies
Melvin Berlin Family Chair in Myeloma Research
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, New York

Scientific Advisory Board: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Omeros, Pfizer Inc, Sanofi Genzyme; Research Support: Actinium Pharmaceuticals Inc, Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Pfizer Inc, Sanofi Genzyme.

Jonathan L Kaufman, MD
Associate Professor of Hematology and Medical Oncology
Winship Cancer Institute of Emory University
Atlanta, Georgia

Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group; Data and Safety Monitoring Board/Committee: TG Therapeutics Inc.

Shaji K Kumar, MD
Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Advisory Committee: AbbVie Inc, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Takeda Oncology; Consulting Agreements: AbbVie Inc, Amgen Inc, Celgene Corporation, Cellectar Biosciences Inc, GeneCentrix Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Molecular Partners, Oncopeptides, Takeda Oncology; Contracted Research (to Institution): AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, CARsgen Therapeutics, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Kite, A Gilead Company, Merck, Novartis, Takeda Oncology, TeneoBio.

Ola Landgren, MD, PhD
Professor of Medicine
Leader, Experimental Therapeutics Program
Leader, Myeloma Program
Sylvester Comprehensive Cancer Center
University of Miami
Miami, Florida

Advisory Committee: Celgene Corporation, Oncopeptides; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides; Contracted Research: Amgen Inc, Janssen Biotech Inc; Independent Data Monitoring Committee: Janssen Biotech Inc; Speakers Bureau: Adaptive Biotechnologies Corporation, Bristol-Myers Squibb Company.

Sagar Lonial, MD
Chair and Professor
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

Joseph Mikhael, MD
Professor
Applied Cancer Research and Drug Discovery
Translational Genomics Research Institute
City of Hope Cancer Center
Phoenix, Arizona

Consulting Agreements: Amgen Inc, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Karyopharm Therapeutics, Sanofi Genzyme, Takeda Oncology.

Nikhil C Munshi, MD
Kraft Family Chair
Director of Basic and Correlative Science
Jerome Lipper Multiple Myeloma Center
Professor of Medicine
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies Corporation, Amgen Inc, BeiGene Ltd, Bristol-Myers Squibb Company, Janssen Biotech Inc, Karyopharm Therapeutics, OncoPep, Takeda Oncology; Ownership Interest: OncoPep.

Robert Z Orlowski, MD, PhD
Florence Maude Thomas Cancer Research Professor
Department of Lymphoma and Myeloma
Professor, Department of Experimental Therapeutics
Director, Myeloma Section
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, EcoR1 Capital LLC, FORMA Therapeutics, Genzyme Corporation, GlaxoSmithKline, Ionis Pharmaceuticals Inc, Janssen Biotech Inc, Juno Therapeutics, a Celgene Company, Kite, A Gilead Company, Legend Biotech, Molecular Partners, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Servier, Takeda Pharmaceuticals North America Inc; Consulting Agreement: STATinMED; Contracted Research: BioTheryX Inc, CARsgen Therapeutics, Celgene Corporation, Exelixis Inc, Janssen Biotech Inc, Sanofi Genzyme, Takeda Pharmaceuticals North America Inc; Ownership Interest: Asylia Therapeutics Inc (founder, patents, equity).

Krina K Patel, MD, MSc
Associate Professor
Center Medical Director
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Advisory Committee: Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Precision BioSciences, Takeda Oncology; Consulting Agreement: Pfizer Inc; Contracted Research: AbbVie Inc, Allogene Therapeutics, Bristol-Myers Squibb Company, Celgene Corporation, Cellectis, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Precision BioSciences, Takeda Oncology.

Noopur Raje, MD
Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Consulting Agreements: Amgen Inc, bluebird bio, Celgene Corporation.

S Vincent Rajkumar, MD
Edward W and Betty Knight Scripps Professor of Medicine
Mayo Clinic
Rochester, Minnesota

No relevant conflicts of interest to disclose.

Nina Shah, MD
Associate Professor of Medicine
University of California, San Francisco
Division of Hematology-Oncology
San Francisco, California

Consulting Agreements: Amgen Inc, CareDx, GlaxoSmithKline, Indapta Therapeutics, Karyopharm Therapeutics, Kite, A Gilead Company, Oncopeptides, Sanofi Genzyme; Contracted Research: bluebird bio, Bristol-Myers Squibb Company, Celgene Corporation, Janssen Biotech Inc, Nektar, Poseida Therapeutics, Sutro Biopharma, TeneoBio.

A Keith Stewart, MB, ChB
Director, Princess Margaret Cancer Centre
VP Cancer, University Health Network
Richard H Clark Chair, Cancer Medicine
Toronto, Canada

Advisory Committee: Amgen Inc, GlaxoSmithKline, Janssen Biotech Inc; Consulting Agreements: Amgen Inc, GlaxoSmithKline, Janssen Biotech Inc, Oncopeptides; Data and Safety Monitoring Board/Committee: Oncopeptides.

Peter Voorhees, MD
Professor of Medicine
Member, Plasma Cell Disorders Division
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina

Advisory Committee: AbbVie Inc, Bristol-Myers Squibb Company; Consulting Agreements: GlaxoSmithKline, Novartis, Oncopeptides; Data and Safety Monitoring Board/Committee: Bristol-Myers Squibb Company.

CONTRIBUTING ONCOLOGISTS — The following contributors reported relevant conflicts of interest, which have been mitigated through a conflict of interest mitigation process:

Spencer Henick Bachow, MD
Hematologist/Oncologist at Lynn Cancer Institute
Affiliate Assistant Professor of Medicine at FAU Schmidt College of Medicine
Boca Raton, Florida

No relevant conflicts of interest to disclose.

Warren S Brenner, MD
Lynn Cancer Institute
Boca Raton, Florida

Speakers Bureau: Celgene Corporation, Takeda Oncology.

Gigi Chen, MD
Diablo Valley Oncology and Hematology Medical Group
Pleasant Hill, California

No relevant conflicts of interest to disclose.

Jay S Dalal, MD
Medical Director
AMITA Health Cancer Institute
Hinsdale, Illinois

No relevant conflicts of interest to disclose.

Lyle Feinstein, MD
Attending Physician
Malignant Hematology and Bone Marrow Transplant
Miami Cancer Institute
Miami, Florida

No relevant conflicts of interest to disclose.

Maria Regina Flores, MD
Physician Partner for Florida Cancer Specialists and Research Institute
Orlando, Florida

No relevant conflicts of interest to disclose.

Rahul Gosain, MD
Division of Hematology and Oncology
Guthrie Corning Cancer Center
Corning, New York

No relevant conflicts of interest to disclose.

Ranju Gupta, MD
Attending Physician
Co-Director, Cardio-Oncology Program
LVPG Hematology Oncology Associates
Lehigh Valley Health Network
Bethlehem, Pennsylvania

Speakers Bureau: Lilly.

Steven Hager, DO
California Cancer Associates for Research and Excellence
Fresno, California

No relevant conflicts of interest to disclose.

Atif Hussein, MD, MMM
Program Director, Hematology/Oncology Fellowship
Medical Director, Oncology Clinical Research
Chairman, Cancer Committee
Memorial Healthcare System
Clinical Associate Professor
Florida International University Herbert Wertheim College of Medicine
Hollywood, Florida

No relevant conflicts of interest to disclose.

Sulfi Ibrahim, MD
Hematology/Oncology
Reid Health
Richmond, Indiana

No relevant conflicts of interest to disclose.

Uqba Khan, MD
Assistant Professor of Clinical Medicine
NewYork-Presbyterian Brooklyn Methodist Hospital
Brooklyn, New York

No relevant conflicts of interest to disclose.

Zanetta S Lamar, MD
Florida Cancer Specialists and Research Institute
Naples, Florida

No relevant conflicts of interest to disclose.

Padmaja Mallidi, MD
Medical Oncologist and Hematologist
Blue Ridge Cancer Care
Roanoke, Virginia

No relevant conflicts of interest to disclose.

Laurie Matt-Amaral, MD, MPH
Attending Physician
Cleveland Clinic Akron General Medical Center
Akron, Ohio

Speakers Bureau: Bristol-Myers Squibb Company.

Neil Morganstein, MD
Hematology Oncology
Atlantic Health System
Summit, New Jersey

No relevant conflicts of interest to disclose.

Benjamin Parsons, DO
Hematology/Oncology
Gundersen Health System Cancer and Blood Disorders
Adult Hematology Section Chair and Pediatric Hematology
Oncology Section Chair
Gundersen Health Site Director for Precision Medicine
Molecular Tumor Board
Clinical Adjunct Professor, University of Wisconsin–Madison
Madison, Wisconsin

No relevant conflicts of interest to disclose.

Shachar Peles, MD
Florida Cancer Specialists and Research Institute
Atlantis, Florida

Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech, a member of the Roche Group, TG Therapeutics Inc, Verastem Inc; Speakers Bureau: Janssen Biotech Inc, Takeda Oncology.

Muzaffar H Qazilbash, MD
Professor of Medicine
Director, Myeloma Transplantation and Cellular Therapy
Department of Stem Cell Transplantation and Cellular Therapy
The University of Texas MD Anderson Cancer Center
Houston, Texas

Contracted Research: Amgen Inc, Angiocrine Bioscience, BioLineRx, Janssen Biotech Inc, NexImmune; Data and Safety Monitoring Board/Committee: Autolus.

Erik J Rupard, MD
Chief, Division of Hematology-Oncology
Tower Health – McGlinn Cancer Institute
West Reading, Pennsylvania

No relevant conflicts of interest to disclose.

Syed Farhan Zafar, MD
Hematologist and Medical Oncologist
Florida Cancer Specialists and Research Institute
Chief, Division of Hematology and Oncology
Lee Health
Fort Myers, Florida

No relevant conflicts of interest to disclose.

PROJECT CHAIR  — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Epizyme Inc, Exact Sciences Inc, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc and Verastem Inc.

USF HEALTH CPD STAFF, RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — No relevant conflicts of interest to disclose.

Commercial Support
These activities are supported by educational grants from Adaptive Biotechnologies Corporation, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, and Takeda Oncology.